Mutation Resistance Could Differentiate Shionogi/ViiV’s Dolutegravir
This article was originally published in Pharmaceutical Approvals Monthly
Full data from the Phase III SPRING-2 trial released at the International AIDS Conference revealed ViiV/Shionogi’s experimental integrase inhibitor dolutegravir had no resistance mutations compared to Merck’s Isentress.
You may also be interested in...
Shionogi Relinquishes HIV Portfolio; Joins Pfizer, GSK As Shareholders In ViiV
Shionogi will clear up cash by turning over global rights to its integrase inhibitor portfolio to its joint venture partner in exchange for royalties and equity in ViiV.
Gilead Files Once-Daily Integrase Inhibitor Elvitegravir With FDA
Part of the Quad combination product, stand-alone elvitegravir could open up the integrase inhibitor market. In a study supporting the single-agent NDA, once-daily elvitegravir proved comparable to Merck’s twice-daily blockbuster Isentress, the only commercially available integrase inhibitor.
Gilead’s Quad Makes It Through FDA Panel Review Despite Renal Safety Concerns
Antiviral Drugs Advisory Committee votes 13-1 in favor of the four-drug-in-one HIV treatment. Panel members offer a host of suggestions for post-marketing studies, including determining the best means for detecting Quad-related renal injury early.